Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| So we're really pleased to see that increase |
| We do believe that, that reinvestment helps partner with these practices, it helps them to grow and it also helps drive our own brand awareness |
| Our differentiated approach has resulted in Jeuveau becoming the fastest-growing toxin in the United States aesthetic market for the third consecutive year |
| During the year, we achieved several major milestones, including the strong execution in the U.S |
| We expect to outpace our competitors with a strong beauty brand, proven products, digital infrastructure and unique strategy targeting millennials, the fastest-growing segment of toxin users in the market |
| And we've seen more and more price competition, and we continue to build our pricing favorably in order to drive the volume |
| So as you can imagine, that creates a great foundation for us to build off of and gave us the confidence we needed to deliver the revision to our guidance for 2024, where we are confident we'll achieve that profitability again in Q4 2024 |
| We are celebrating our fifth year of Jeuveau being on the market in May, and are proud to have achieved double-digit market share despite new competitive entrance |
| I'm proud of the innovative culture we've built at Evolus and the tenacity of our team |
| As it relates to how much profitability, I think we'll continue to assess that throughout the year, but we have great momentum going into 2024, and we continue to have disciplined operating expense management |
| We are very pleased to report on another record quarter and 2023 full year results while consistently focusing on delivering on our long-term strategy of leading the performance beauty market |
| The combination of strong execution and the expansion of our portfolio with Evolus and Estyme put us well on our way to achieving our 2028 revenue goal of at least $700 million |
| These milestones reinforce the global demand for our consumer brand, the high quality of our products and the competitive moat we built as the first company focused on cash-based aesthetics |
| That's the highest unit share we've achieved since launch |
| The continued strength of our flagship toxin and growing brand loyalty will drive meaningful growth this year as we look to expand our share in the U.S |
| And as you may know, we are launching in Europe around the same time as Hugel, the Letybo product, and we've continued to very well in those markets |
| In 2023, we achieved a record global revenue of $61 million for the fourth quarter and $202 million for the full year, representing 40% and 36% growth over the prior year, respectively |
| The full year results surpassed the top end of our guidance of $198 million due to our growing consumer demand and continued market share gains |
| Our fourth quarter revenue increase of 40% over the prior year quarter and 22% sequentially were both multiples above the estimated industry growth rate |
| And importantly, our back half growth accelerated meaningfully above the first half, driving continued market share gains with Jeuveau and resulted in our market share, achieving 12% in the fourth quarter |
| We're really proud of what the team has done, and we'll continue to see really strong execution from them |
| So that gives us a very good confidence in the fact that our share gains, even in established customers still has a lot of opportunity for growth |
| I think what's unique is our value proposition in the market, and we'll continue to build on that, and we believe that will drive meaningful growth in the future |
| I think as Sandra just commented, our pricing has been very strong |
| So we were equally, frankly, as impressed by the numbers that the field brought in of new customers |
| We saw very healthy trends in the back half of last year, I think you observed not just in our revenue acceleration, but you observed a broader market |
| that reported that they had reported strong trends from consumer demand |
| So it's a good year, off to a good start as we expected |
| Excluding share issuance for the European filler license recorded as IPR&D expense, the fourth quarter non-GAAP operating income was a positive $0.7 million, representing continued progress to sustain profitability |
| We continue to experience strong pricing in the U.S |
| Statement |
|---|
| As a point of note, due to onetime filler launch expenses within 2025, profitability may not be achieved every quarter |
| And then generally, the third quarter is the weakest season of the calendar year |
| And so we'll continue to add new accounts as we receive them, but we're limited by just our ability to run them through the proper steps that believe, lead to a productive customers |
| Nothing unusual |
| I was just curious if your guidance includes some upcoming competition from -- in the U.S |
Please consider a small donation if you think this website provides you with relevant information